RBC Capital Lowers CYH Price Target to $5.00 from $6.00, Maintains "Outperform" Rating
ByAinvest
Sunday, Jul 27, 2025 5:42 am ET1min read
CYH--
Based on the one-year price targets offered by 8 analysts, the average target price for CYH is $3.72, with a high estimate of $5.00 and a low estimate of $3.00. This implies an average upside of 28.23% from the current price of $2.90 [1]. The consensus recommendation from 10 brokerage firms indicates a "Hold" status, with an average rating of 2.9 [1]. GuruFocus estimates the GF Value for CYH in one year to be $3.51, suggesting an upside of 21.03% from the current price of $2.9 [1].
CYH reported a 6.5% year-over-year increase in same-store net revenue for the second quarter but experienced a decline in adjusted admissions by 0.7%. Inpatient admissions increased by 0.3%, while same-store surgeries and emergency room visits declined by 2.5% and 1.9%, respectively. The company's adjusted EBITDA was $380 million, down from $387 million in the prior year period, and the EBITDA margin decreased to 12.1% from 12.3% [1].
RBC Capital's updated price target reflects the company's reassessment of CYH's market positioning while still indicating a positive outlook for its performance. The average target price for CYH is $3.72, with a high estimate of $5.00 and a low estimate of $3.00, implying an average upside of 30.25% from the current price of $2.86 [1].
References:
[1] https://www.gurufocus.com/news/3005142/community-health-cyh-price-target-reduced-by-rbc-capital-amid-volume-concerns-cyh-stock-news
RBC Capital maintains "Outperform" rating for CYH but lowers price target from $6.00 to $5.00, representing a 16.67% decrease. The updated price target reflects RBC Capital's reassessment of CYH's market positioning while still indicating a positive outlook for the company's performance. The average target price for Community Health Systems Inc is $3.72 with a high estimate of $5.00 and a low estimate of $3.00, implying an upside of 30.25% from the current price of $2.86.
RBC Capital has revised its price target for Community Health Systems Inc (CYH) from $6.00 to $5.00, while maintaining an "Outperform" rating. The adjustment reflects the firm's concerns over CYH's lower-than-expected adjusted admissions in the second quarter, which has led to a cautious outlook for the remainder of the year. This development adds to existing volume-related worries for the company [1].Based on the one-year price targets offered by 8 analysts, the average target price for CYH is $3.72, with a high estimate of $5.00 and a low estimate of $3.00. This implies an average upside of 28.23% from the current price of $2.90 [1]. The consensus recommendation from 10 brokerage firms indicates a "Hold" status, with an average rating of 2.9 [1]. GuruFocus estimates the GF Value for CYH in one year to be $3.51, suggesting an upside of 21.03% from the current price of $2.9 [1].
CYH reported a 6.5% year-over-year increase in same-store net revenue for the second quarter but experienced a decline in adjusted admissions by 0.7%. Inpatient admissions increased by 0.3%, while same-store surgeries and emergency room visits declined by 2.5% and 1.9%, respectively. The company's adjusted EBITDA was $380 million, down from $387 million in the prior year period, and the EBITDA margin decreased to 12.1% from 12.3% [1].
RBC Capital's updated price target reflects the company's reassessment of CYH's market positioning while still indicating a positive outlook for its performance. The average target price for CYH is $3.72, with a high estimate of $5.00 and a low estimate of $3.00, implying an average upside of 30.25% from the current price of $2.86 [1].
References:
[1] https://www.gurufocus.com/news/3005142/community-health-cyh-price-target-reduced-by-rbc-capital-amid-volume-concerns-cyh-stock-news
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet